Close Menu

NEW YORK – As the broader stock market tanked last week amid fears of a coronavirus pandemic, the shares of companies in the genomics research tools and molecular diagnostics markets were not immune to the selloff.

The awful week for publicly traded stocks pulled the GenomeWeb Index down 7 percent for the month of February. In comparison, the Dow Jones Industrial Average fell 11 percent, the Nasdaq declined 8 percent, and the Nasdaq Biotech Index only dropped 2 percent month over month.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.